WillItSurvive
Medical technology and health companies · United States

Tandem Diabetes Care

tandemdiabetes.com ↗

Tandem makes wearable insulin pumps with automated dosing algorithms for diabetes.

Losing its protection
Assessed 22 July 2026 · Evidence as of 22 July 2026
The structural protection is eroding.
On the recordSince 22 July 2026 · Checkable from late 2026 · Every call on the record Checkpoint: Freedom fully closed-loop pivotal trial launch, ahead of a 2027 FDA filing
The call

Tandem ships real, cleared hardware and just crossed $1 billion in sales, but it is losing the growth race to Insulet while carrying debt and litigation risk.

Tandem Diabetes Care makes automated insulin pumps that deliver medicine based on blood sugar levels. The company has real FDA approvals and clinical proof that its pump works, including permission to market it for pregnant women. However, Omnipod, a competitor nine times larger, is growing faster and has already matched Tandem's clinical results and regulatory approvals, so Tandem's advantages are shrinking. The company is not yet profitable, owes a lot of money relative to its size, and faces a lawsuit that creates uncertainty for investors. One big trial called Freedom, expected to start late 2026 and file results with regulators in 2027, could show whether Tandem can catch up or falls further behind.

Why
01
AI pressure: None apparent. Control-IQ+ is Tandem's own dosing algorithm, not a third-party AI model that could replace the company. Could AI do the core job? Unlikely.
02
Bigger players: Insulet Corporation (Omnipod 5). Insulet is 9x Tandem's market cap, growing 20%+ for ten straight years, and capturing most new AID pump growth. Could a giant copy it? Probably.
03
What protects it. FDA clearances patients already rely on, including the only approved pregnancy indication, plus the hassle of switching pumps.
What would change this call
Tandem's Freedom fully closed-loop pivotal trial starts and reports data on schedule (targeted late 2026/2027 filing). Shows whether Tandem can match Insulet's EVOLVE program or falls further behind.
Insulet launches Omnipod 6 in 2027. Would test whether Insulet extends its lead in AID pump share over Tandem.
Q2 2026 earnings (August 6, 2026) revenue and margin results versus ~$1.1B FY2026 guidance. Shows whether Tandem's growth and path to profitability are holding up.
Key numbers
  • FY2025 revenue hit $1.015 billion, first time over $1B (2025-12-31)
  • Trailing EPS is -$1.40, still unprofitable (2026-03-31)
  • Market cap around $1.2B versus Insulet's ~$11.3B (2026-07-22)
Named risks
  • Ongoing securities class-action investigation tied to August 2025 t:slim X2 speaker-defect disclosure. Severity: high
  • High leverage with debt-to-equity of 4.54 and new $265-300M convertible notes due 2032. Severity: high
  • Persistent GAAP unprofitability (trailing EPS -$1.40) despite revenue growth. Severity: medium
  • Losing growth race to Insulet, which is 9x larger by market cap and outpacing AID market growth. Severity: high
  • New product-liability litigation (Burdick v. Tandem filed May 2026) continuing legal exposure. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Insulet Corporation (Omnipod 5)losing to9x larger market cap ($11.3B vs $1.2B) as of 2026-07-22, 10 straight years 20%+ growth through FY2025
Insulet Corporation (EVOLVE trial)losing toInsulet's fully closed-loop EVOLVE pivotal trial started 2026-05-04, ahead of Tandem's Freedom trial
Medtronic (MiniMed 780G)contestingLarger diversified incumbent competing in same AID pump market, no direct 2026 dated clash cited
Beta Bionics (iLet Bionic Pancreas)contestingSmaller simplified AID competitor in same category, no dated share data provided
Abbott (FreeStyle Libre) and DexcomcontestingTandem depends on their CGM sensors; partnered with Abbott Libre 3 Plus launch 2026-07-01
Questions people ask
Is Tandem Diabetes Care profitable in 2026?
No. Tandem posted a Q1 2026 EPS of -$0.30 with trailing EPS of -$1.40, despite revenue of $247.22 million (up 5.5% year-over-year) as of March 31, 2026. FY2025 revenue hit $1.015 billion but the company remains GAAP unprofitable.
Who is Tandem Diabetes Care's biggest competitor?
Insulet Corporation (Omnipod 5) is Tandem's chief rival, with a market cap around $11.3 billion versus Tandem's $1.2 billion as of July 22, 2026. Insulet reported 20%+ constant-currency revenue growth for ten straight years through FY2025, outpacing Tandem's growth.
Could AI replace Tandem Diabetes Care's products?
Unlikely soon. Tandem's Control-IQ+ is a proprietary, FDA-cleared algorithm embedded in regulated hardware (t:slim X2, Tandem Mobi), not a third-party AI model. FDA clearance for pregnancy use in type 1 diabetes came April 27, 2026, reinforcing a regulatory moat against generic AI substitution.
Is Tandem Diabetes Care laying off workers in 2026?
Headcount contracted an estimated 5 to 9% in 2025: Macrotrends reports 2,500 employees at end of 2025 (down from 2,650 in 2024), while Revelio Labs estimates about 2,179 employees in December 2025, down 9.4% from 2,395 in 2024.
What is Tandem Diabetes Care's newest product pipeline focus?
Tandem is developing the Freedom fully closed-loop AID system, with early efficacy data on high-carb/high-fat meals published November 14, 2025, and a pivotal trial targeted to begin later in 2026 ahead of an anticipated 2027 FDA filing.
Does Tandem Diabetes Care have legal or regulatory trouble in 2026?
Yes. An August 2025 t:slim X2 speaker-defect correction triggered a Rosen Law Firm securities class-action investigation disclosed January 31, 2026. A new product-liability suit, Burdick v. Tandem, was filed May 18, 2026, though an earlier case (Gallego) was dismissed with prejudice in April 2026.
Timeline
  • 2026-07-01t:slim X2 launches with Abbott FreeStyle Libre 3 Plus CGM in 5 European markets
  • 2026-06-04UPMC study finds similar long-term outcomes for Control-IQ and Omnipod 5 users
  • 2026-05-18New product-liability suit Burdick v. Tandem filed in D. Colorado
  • 2026-05-04Insulet enrolls first patient in EVOLVE closed-loop pivotal trial for type 2 diabetes
  • 2026-04-27FDA clears Control-IQ+ for use during pregnancy with type 1 diabetes
  • 2026-04-27Gallego v. Tandem product-liability case dismissed with prejudice
  • 2026-02-25Tandem prices upsized $265-300M convertible senior notes due 2032
  • 2026-02-19FY2025 results announced: $1.015B revenue, first time surpassing $1B
  • 2026-01-31Rosen Law Firm discloses securities class-action investigation into TNDM
  • 2025-08-01Voluntary correction issued for t:slim X2 pumps over speaker-related insulin issue
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources